Atypical incessant myeloid leukemia may be a sort of leukemia. It may be a heterogeneous clutter having a place to the gather of myelodysplastic/myeloproliferative (MDS/MPN) disorders. In aCML numerous clinical highlights and research facility anomalies recommend the conclusion of unremitting myelogenous leukemia. In any case the need of the pathognomonic Philadelphia chromosome and of the coming about BCR-ABL1 combination point to a diverse pathogenetic handle. Since no particular repetitive genomic or karyotypic anomalies have been distinguished in aCML, the atomic pathogenesis of this malady has remained tricky and the result dreary with no change over the final 20 a long time. This strongly contrasts with the result for CML, for which the guess was significantly progressed by the improvement of imatinib as a particular inhibitor of the BCR-ABL protein and in specific for CML.
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Short Communication: Journal of Cancer Clinical Trials
Short Communication: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Posters & Accepted Abstracts: Journal of Clinical Case Reports
Posters & Accepted Abstracts: Journal of Clinical Case Reports
Posters & Accepted Abstracts: Journal of AIDS & Clinical Research
Posters & Accepted Abstracts: Journal of AIDS & Clinical Research
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Posters & Accepted Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report